Dr. Chris Dale, Vice President, Technology, Cambrex Biopharmaceuticals and Dr. Robert N. Brey, Chief Scientific Officer, DOR Bio
September 15 2005 - 5:41PM
PR Newswire (US)
EAST RUTHERFORD, N.J. and MIAMI, Sept. 15 /PRNewswire-FirstCall/ --
Cambrex Corporation (NYSE:CBM) and DOR BioPharma, Inc. (AMEX:DOR)
are pleased to announce that Chris Dale, Ph.D., Vice President,
Technology, Cambrex Biopharmaceuticals business and Robert N. Brey,
Ph.D., Chief Scientific Officer, DOR BioPharma will be speakers at
the BioProcess International(TM) World 2005 Conference and
Exhibition in Boston, Massachusetts, USA on Monday, September 19,
2005 at 11:45 am ET. (Logo:
http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO ) Dr. Dale
and Dr. Brey will present a case study on the rational development
of a cost effective manufacturing process for the production of
RiVax(TM), a ricin vaccine developed by DOR BioPharma's biodefense
division. Cambrex is providing DOR with process development and
cGMP production services. Cambrex successfully reengineered the low
yielding and inefficient laboratory scale process and made a
substantial improvement in productivity and yield of RiVax. The
manufacturing process will be reviewed with respect to a cost of
goods approach in the context of a vaccine procurement program.
Chris Dale, Ph.D., Vice President, Technology of the Cambrex
Biopharma business, has over twenty years of experience in
recombinant and native protein purification and over fifteen years
experience of fermentation/cell culture in bacterial, yeast and
mammalian systems gained in academic and industrial positions.
Prior to joining Cambrex, Dr. Dale held positions at Covance
Biotechnology Services and SmithKline Beecham. Dr. Dale holds a BSc
in Microbiology from Coleg Prifysgol Cymru and a Ph.D. in
Biochemistry from the University of Birmingham. Dr. Robert Brey,
Chief Scientific Officer, has been at DOR BioPharma since 1996.
Previously, he held scientific and management positions in the
Lederle-Praxis division of American Cyanamid, now a division of
Wyeth. From 1996 through 1998, in addition to serving as Vice
President of DOR BioPharma, he served as Corporate Vice President
of InnoVaccines Corporation, a joint venture with Elan
Pharmaceutical Technologies. From 1994 through 1996, Dr. Brey
established the Vaccine Design Group to identify and develop novel
vaccine technologies and platforms. Before entering into drug and
vaccine delivery, he held senior scientific positions at Genex
Corporation, one of the first biotechnology companies formed to
exploit genetic engineering. Dr. Brey received an undergraduate
degree in biology from Trinity College in Hartford, Connecticut,
his Ph.D. in microbiology from the University of Virginia and
performed postdoctoral studies at MIT with Nobel laureate Salvador
Luria. Dr. Brey is an inventor or co-inventor of ten U.S. patents
in the area of vaccines. For conference information, please visit
http://www.ibclifesciences.com/BPI/US/. About Cambrex Cambrex is a
global, diversified life sciences company dedicated to providing
products and services to accelerate and improve the discovery and
commercialization of human therapeutics. The Company employs
approximately 1900 worldwide. For more information, please visit
http://www.cambrex.com/. About DOR BioPharma, Inc. DOR BioPharma,
Inc. is a biopharmaceutical company focused on the development of
therapeutic products and biomedical countermeasures for areas of
unmet medical need. Their lead product, orBec(R) (oral
beclomethasone dipropionate), is a potent, locally-acting
corticosteroid being developed for the treatment of intestinal
Graft-versus-Host disease (iGVHD), a common serious complication of
bone marrow transplantation for cancer, as well as other
gastrointestinal disorders characterized by severe inflammation.
DOR BioPharma intends to file a new drug application (NDA) with the
FDA for orBec(R) for the treatment of iGVHD later this year.
Through the BioDefense Division, DOR BioPharma is developing
biomedical countermeasures pursuant to the paradigm established by
the recently enacted Project BioShield Act of 2004. The biodefense
products in development are bioengineered vaccines designed to
protect against the deadly effects of ricin toxin and botulinum
toxin, both of which are considered serious bioterrorism threats.
The ricin toxin vaccine, RiVax(TM), is currently the subject of a
Phase I clinical trial in normal volunteers. DOR BioPharma has also
initiated a new botulinum toxin therapeutic development program
based on rational drug design. For further information regarding
DOR BioPharma, please visit the Company's website located at
http://www.dorbiopharma.com/. RiVax(TM) and orBec(R) are trademarks
of DOR Biopharma, Inc
http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO
http://photoarchive.ap.org/ DATASOURCE: Cambrex Corporation
CONTACT: Anne-Marie Hess, Director, Investor Relations &
Corporate Communications of Cambrex Corporation, +1-201-804-3062,
Web site: http://www.cambrex.com/ http://www.dorbiopharma.com/
http://www.ibclifesciences.com/BPI/US Company News On-Call:
http://www.prnewswire.com/comp/134219.html
Copyright
Dor (AMEX:DOR)
Historical Stock Chart
From Jul 2024 to Aug 2024
Dor (AMEX:DOR)
Historical Stock Chart
From Aug 2023 to Aug 2024